Drug Trial Radar · NCT07804901
Asciminib Frontline Risk Adapted
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Dec 31, 2030
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- Prof. Dr. med. Andreas HochhausAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib. The study will be conducted in Germany.
Conditions
- Chronic Myeloid Leukemia (CML)
Interventions
Dasatinib 80mg QD (5 days per week)Drug
Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib.
Standarc of CareDrug
Asciminib 80mg QD ist the usual standard of care therapy for CML
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of MMR at 12 monthsTime frame: 12 months after start of therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitätsklinikum Jena
Jena, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.